Showing 1 posts of 1 posts found.
Alnylam Pharmaceuticals’ shares lost close to half of their value as it was forced to end a trial of its …
Product value to pathway impact: What the CVD Modern Service Framework means for pharma
Functional lung imaging offers new possibilities for respiratory care
Five Facts about cardiovascular disease
Data integrity: the keystone for AI adoption, patient safety and organisational reputation
Artificial hearts: a century of innovation